Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study on the Safety and Efficacy of Orlistat in Third-generation EGFR-TKI Resistance

NCT06818955 is registered in ClinicalTrials.gov with Ping Peng as lead sponsor.

NCT NCT06818955
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06818955 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study on the Safety and Efficacy of Orlistat in Third-generation EGFR-TKI Resistance
Lead sponsor
Ping Peng
Phase
Phase 2
Overall status
Not yet recruiting
Start date
February 16, 2025
Completion date
November 15, 2025
Enrollment
36 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

lung adenocarcinoma, osimertinib